# name
Effectiveness of single-dose azithromycin to treat latent yaws:
                a longitudinal comparative cohort study

# metadata.dc.description.abstract[].value
BACKGROUND: Treatment of latent yaws is a crucial component of
                the WHO yaws eradication strategy to prevent relapse and the
                resulting transmission to uninfected children. We assessed the
                effectiveness of single-dose azithromycin to treat patients with
                latent yaws. METHODS: This population-based cohort study
                included children (age <20 years) living on Lihir Island,
                Papua New Guinea, with high-titre (rapid plasma reagin titre
                >/=1:8) latent or active yaws, between April, 2013, and May,
                2015. Latent yaws was defined as lack of suspicious skin lesions
                or presence of ulcers negative for Treponema pallidum subsp
                pertenue on PCR, and active yaws was defined as ulcers positive
                for T pertenue on PCR. All children received one oral dose of 30
                mg/kg azithromycin. The primary endpoint was serological cure,
                defined as a two-dilution decrease in rapid plasma reagin titre
                by 24 months after treatment. Treatment of latent yaws was taken
                to be non-inferior to that of active yaws if the lower limit of
                the two-sided 95% CI for the difference in rates was higher than
                or equal to -10%. This study is registered with
                ClinicalTrials.gov, number NCT01955252. FINDINGS: Of 311
                participants enrolled, 273 (88%; 165 with latent yaws and 108
                with active yaws) completed follow-up. The primary endpoint was
                achieved in 151 (92%) participants with latent yaws and 101
                (94%) with active yaws (risk difference -2.0%, 95% CI -8.3 to
                4.3), meeting the prespecified criteria for non-inferiority.
                INTERPRETATION: On the basis of decline in serological titre,
                oral single-dose azithromycin was effective in participants with
                latent yaws. This finding supports the WHO strategy for the
                eradication of yaws based on mass administration of the entire
                endemic community irrespective of clinical status. FUNDING:
                Newcrest Mining Limited and ISDIN laboratories.

# metadata.dc.source[].value
Articles publicats en revistes (ISGlobal)

# metadata.dc.title[].value
Effectiveness of single-dose azithromycin to treat latent yaws:
                a longitudinal comparative cohort study